Goodbody

Goodbody Asset Management

Goodbody Global Leaders Fund

- 'Own the Best, Not the Rest' Resilience, Adaptability, Execution
- ResMed (+18%) and DSV Panalpina (+14%) top performers in June

Fund performance

The Fund outperformed what was another strong month for global equity markets in June. Stock selection, notably within the Fund's Healthcare holdings, was the primary driver of relative performance. ResMed (+18%), the leading player in the treatment of sleep apnea, and DSV Panalpina (+14%), one of the largest global freight forwarding companies, were among the top contributors to performance. The first half of 2020 has been a tough environment for equity markets, acting as a real-time litmus test of the performance of active equity funds. Against this backdrop, the Goodbody Global Leaders Fund is meaningfully ahead of its benchmark, producing a resilient return for investors.

Value of €10,000 invested



Source: New Ireland, Bloomberg

Why consider the Goodbody Global Leaders Fund?

1. More profitable today

Invest in a select group of dominant companies with sustained leadership positions. These are among the most profitable companies in their industry.

2. More profitable tomorrow

The fund invests in companies with some of the best track records of successful innovation. Such innovation sustains their leadership positions. These leaders of today can also be the most profitable companies of tommorrow.

3. Investment opportunity

Global Leaders present a compelling risk/reward opportunity as they consistently widen the gap with competitors. This can lead to significant share price outperformance over time.

Warning: Past performance is not a reliable guide to future performance.




For Financial Advisors Only

The **Goodbody Global Leaders Fund**, an actively-managed, concentrated, global equity fund invests in a diversified portfolio of 40 companies that dominate their industries. The fund aims to outperform the MSCI World Index by 2 - 3% per annum over the medium to long-term.

Key information

Fund launch date	3 March 2016
Base currency	€
Pricing/Dealing	Daily
Month end unit price (€)	1.80
Number of holdings	35
Top 10 holdings as a % of t	he fund 32%
Active share*	91%


Geographic mix as at 30 June 2020



North America	81%
Europe (ex. UK)	9%
Asia Pacific (ex. Japan)	5%
UK	3%
Japan	2%
Source: Goodbody	

Performance is shown gross of taxation and gross of fund management fees.

Sector split as at 30 June 2020



Source: Goodbody

Market commentary

June finished a very strong second quarter for global equity markets – the MSCI World Index gained 1.7% in euro terms over the month. Fiscal and monetary support were key drivers behind the continued rebound. The ECB raised its pandemic bond buying program by €600bn to €1.35tn and extended the program until June 2021. The Fed reiterated its ultra-accommodative policy for the foreseeable future, with interest rates unlikely to rise before the end of 2022. A significant bounce back in monthly economic data, albeit from depressed levels, also helped underpin sentiment. Conversely, cases of Covid-19 continued to increase globally, most notably in the US. Within equity markets, Technology and Consumer Discretionary sectors outperformed while Utilities and Healthcare, both traditionally defensive sectors, lagged the broader market. Gold continued its steady push higher, gaining an additional 1.5% in June. In US politics, Joe Biden took a commanding lead in the US presidential election polls.

Warning: The value of your investment may go down as well as up.

Warning: This fund may be affected by changes in currency exchange rates.

Warning: If you invest in this fund you may lose some or all of the money you invest.

*Active Share is a measure of the Fund's overlap with the benchmark. An active share of 100% indicates that the Fund has no holdings in common with the benchmark and active share of 0% indicates a Fund that tracks the benchmark.

The Fund is a unit linked fund of the life company. The value of your life assurance policy is linked to the performance of the Fund. Please contact your financial adviser or New Ireland to make additional premiums. Please refer to your policy documentation for information on fees, charges and risks that apply to your investment.

This publication has been approved by Goodbody Stockbrokers UC. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

This document is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this publication constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. Registered Office: Ballsbridge Park, Ballsbridge Dublin 4, Ireland. T: +353 1 667 0400. Registered in Ireland No. 54223.

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland. In the UK, Goodbody is also subject to regulation by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a member of the FEXCO group of companies. 000803_0720



Goodbody

Contact us today

Goodbody Asset Management, 2 Ballsbridge Park, Ballsbridge, Dublin 4 T +353 1 641 9470 E assetmanagement@goodbody.ie W www.goodbody.ie/assetmanagement

Top 10 holdings as at 30 June 2020

Microsoft	3.5%
Tractor Supply	3.4%
Agilent Technologies	3.3%
IDEXX Laboratories	3.2%
Sika	3.2%
Moody's	3.2%
Alphabet	3.2%
Hermés	3.1%
Ansys	3.1%
ResMed	3.0%

Source: Goodbody